Human Cell Panel and CDX Models
Facilitating novel anti-cancer drug discovery.
Human cancer cell panels have long been a valuable tool in anti-cancer drug discovery: they assess the potential cytotoxicity and growth-inhibition effects of the tested compounds against different types of tumors. Human cancer cell panels are not devoid of limitations, but they remain a far-reaching tool in oncology and immuno-oncology.
At PharmaLegacy, we provide our clients with more than 300 cancer cell lines for in vitro characterizations and over 270 well-validated cell line-derived xenograft (CDX) models for in vivo applications.
MODELS / SERVICES
- 300+ Cancer Cell Lines for anti-cancer drug discovery, enabling rapid and efficient evaluation of potential cytotoxicity and growth-inhibition effects of test compounds.
- Genetic annotation with CCLE panel
- High-quality cell identification guaranteed with periodical STR examination and mycoplasma testing
| Tumor Type | # of Cell Lines |
|---|---|
| Brain | 6 |
| Breast | 22 |
| Colon | 26 |
| Gastric | 19 |
| Esophagus | 5 |
| Kidney | 6 |
| Leukemia | 21 |
| Liver | 13 |
| Lung | 51 |
| Lymphoma | 23 |
| Melanoma | 8 |
| Multiple myeloma | 5 |
| Ovary | 10 |
| Pancrease | 12 |
| Prostate | 10 |
| Sarcoma | 6 |
| Other Tumor Types | > 40 |
| Normal Cell Lines | 10 |
Case Study:
Cell Line-Derived Xenograft (CDX) Models
Over 260 validated CDX models spanning solid and hematologic malignancies, available in subcutaneous, orthotopic, systemic, and dual-tumor inoculation formats. These models allow fast transition from in vitro screening to in vivo efficacy, PK/PD correlation, biomarker analysis, and drug-resistance profiling. Data bank of Standard of Care (SOC) responses are available for most models.
We provide:
- No leading time before study initiation
- Consistent tumor engraftment with robust historical control data for reference
- Options and dosing regimen ranges for comparative and combination efficacy assessments.
- Frequent data updates (at least twice per week), timely communication, and feedback responses on project progress to facilitate data-driven decisions from target validation, in vivo proof-of-concept studies to IND enabling packages.
To date, Pharmalegacy’s Oncology and Immuno-Oncology platform offers more than 700 in vivo models, including CDX (300+), PDX (350+) and syngeneic models (50+) among these, 90+ are orthotopic & experimental metastasis models, 100+ are humanized (huPBMC or HSC) models and about 30 drug resistance models. We provide multi‑omic profiling data for each resistance model and support in‑depth bioinformatic analyses. This comprehensive platform significantly improves the translational efficiency of drug discovery and accelerates the path of more anti-resistance therapeutics to clinic.
PharmaLegacy boasts extensive expertise in developing bone metastasis models, offering a thorough and comprehensive set of evaluation criteria related to bone cancer. The experimental bone metastasis models can achieve metastasis incidence rate. We provide fully validated models for bone metastasis induced by intracardiac or intratibial injections, specifically for breast and prostate cancers. Additionally, we have established several spontaneous bone metastasis models through the continuous enhancement of our surgical techniques for tumor implantation. This allows us to offer a diverse array of models of bone metastasis. Furthermore, our specialized services extend to evaluating drug mechanisms of action through in vitro tumor biology and ex vivo molecular pharmacology methods, facilitating early proof-of-concept assessments for drug development candidates.
The capability to succeed:
- AAALAC accredited vivarium
- Research data electronically managed by BioBook (IDBS, UK)
- 1,500+ validated animal models of disease spanning 100+ indications
- PK/PD, molecular pharmacology and preliminary toxicology adjacency studies
Seeking uncompromising quality with deep skills and knowledge? Contact PharmaLegacy.
Providing Better Data for Critical Immuno-Oncology Pipeline Decisions
PharmaLegacy works to get you the answers you need with our wide selection of carefully developed in vivo and in vitro models. In this document, you’ll see a sample of the in vitro assays we run along with a sample of real-world data from them. See why over 700 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.
